Cholestyramine in uraemic pruritus

Area of Science:

• Nephrology
• Dermatology
• Pharmacology

Background:

• Uraemic pruritus is a common and debilitating symptom in patients with chronic kidney disease undergoing haemodialysis.
• Current treatments for uraemic pruritus are often ineffective or have significant side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of cholestyramine in treating uraemic pruritus in patients on chronic haemodialysis.

Main Methods:

• A four-week, randomized, double-blind, placebo-controlled study was conducted.
• Ten patients with uraemic pruritus on chronic haemodialysis were enrolled.
• Patients received either cholestyramine or a placebo.

Main Results:

• Four out of five patients treated with cholestyramine experienced considerable improvement in pruritus.
• Only one out of five patients in the placebo group reported relief.
• Increased cholestyramine dosage further improved symptoms in a non-responder.
• Side effects were mild, reversible (constipation, nausea), and did not necessitate treatment discontinuation.

Conclusions:

• Cholestyramine appears to be a potentially useful treatment for uraemic pruritus.
• Further research is needed to elucidate the mechanism of action of cholestyramine in uraemic pruritus.